Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
$0.42
+2.6%
$0.51
$0.07
$1.45
$466.87M1.77141,517 shs261,238 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$12.57
+0.1%
$12.82
$9.03
$17.70
$875.92M1.19537,092 shs637,973 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
-22.87%-22.87%-5.56%-32.61%-66.14%
Zymeworks Inc. stock logo
ZYME
Zymeworks
0.00%-5.70%-2.06%-3.01%+20.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.8692 of 5 stars
3.54.00.00.01.93.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
0.00
N/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0067.06% Upside

Current Analyst Ratings Breakdown

Latest WIZP, CNTTF, ZYME, and CXRXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$13.00
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/A$0.03 per shareN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M9.38N/AN/A$6.63 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)

Latest WIZP, CNTTF, ZYME, and CXRXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52N/AN/AN/A$17.18 millionN/A
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/A
1.13
1.13
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
2486.32 millionN/ANot Optionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.68 million67.56 millionOptionable

Recent News About These Companies

Zymeworks (ZYME) Projected to Post Earnings on Thursday

New MarketBeat Followers Over Time

Media Sentiment Over Time

CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Mawson Infrastructure Group stock logo

Mawson Infrastructure Group OTCMKTS:WIZP

$0.42 +0.01 (+2.56%)
As of 08/1/2025

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$12.57 +0.01 (+0.08%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$12.57 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.